MET its match.

MET-mutations are notorious for causing resistance to EGFR-TKIs while remaining elusive to successful targeted therapy itself. This large early-phase expansion study of combo osimertinib plus the MET-inhibitor savolitinib demonstrates responses in over half of patients with MET-amplified NSCLC failing alternative EGFR-TKIs. | Sequist, Lancet Oncol 2020